Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Pfizer
(NY:
PFE
)
22.83
+0.23 (+1.02%)
Official Closing Price
Updated: 7:00 PM EDT, May 16, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Pfizer
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
99
100
Next >
2 No-Brainer Healthcare Stocks to Buy With $500 Right Now
February 21, 2025
Via
The Motley Fool
Large Cap Biopharmaceutical Metrics And Performance Q1 2025
February 20, 2025
Tariffs could have big impact on earnings in 2025.
Via
Talk Markets
Topics
Stocks / Equities
Curious about the most active S&P500 stocks in today's session?
February 20, 2025
Explore the S&P500 index on Thursday and find out which stocks are the most active in today's session. Stay updated with the stocks that are capturing market interest.
Via
Chartmill
What's Driving the Market Sentiment Around Pfizer?
February 20, 2025
Via
Benzinga
The Smartest Dividend Stocks to Buy With $1,000 Right Now
February 20, 2025
Via
The Motley Fool
3 Things You Need to Know If You Buy Pfizer Today
February 18, 2025
Via
The Motley Fool
Are Investors Being Too Paranoid About Pfizer Stock?
February 13, 2025
Via
The Motley Fool
Pfizer's Options Frenzy: What You Need to Know
February 11, 2025
Via
Benzinga
Which S&P500 stocks are the most active on Wednesday?
February 19, 2025
Explore the S&P500 index on Wednesday and find out which stocks are the most active in today's session. Stay updated with the stocks that are capturing market interest.
Via
Chartmill
Trade War Redux: These ETFs Due For Bumpy Ride Thanks To Trump Tariffs On Auto, Pharma, Chip Imports
February 19, 2025
Trump's proposed 25% tariffs on auto, semiconductor, and pharmaceutical imports have rattled markets and could affect ETFs with heavy exposure to these sectors.
Via
Benzinga
Topics
ETFs
Government
World Trade
Exposures
Political
Tariff
Rule Breaker Investing Stock Stories, Vol. 10: Frosty Campfire, Fiery Stocks
February 19, 2025
Every stock tells a story; it takes humans to find the meaning in it.
Via
The Motley Fool
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields
February 19, 2025
Via
Benzinga
Love, Money, and Stocks
February 18, 2025
Via
The Motley Fool
Which S&P500 stocks are the most active on Tuesday?
February 18, 2025
Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Tuesday. Discover the stocks that are generating the highest...
Via
Chartmill
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.’s Board Of Directors For Breach of Fiduciary Duties (NYSE: PFE)
February 18, 2025
From
Berger Montague
Via
GlobeNewswire
Trump's Tax Cut Could Add $4.6 Trillion To Deficit, With $48 Billion Tax Relief For Top 100 Firms: Robert Reich
February 18, 2025
Robert Reich has termed Donald Trump's taxation policies as an "absolutely shameless giveaway," that could shoot up deficit to $4.6 trillion.
Via
Benzinga
Topics
Government
Exposures
Political
Health Insurance ETFs in Focus as RFK Jr Takes Over HHS
February 17, 2025
Robert F. Kennedy Jr. has taken office as HHS secretary, which could impact the healthcare sector, including ETFs with exposure to insurers like UnitedHealth and Elevance Health.
Via
Benzinga
Topics
ETFs
Ken Griffin's Citadel Places Big Short Bet Against GSK - Here's What It Means for Investors
February 17, 2025
Ken Griffin's Citadel hedge fund places £305M short bet against GSK, with skepticism over long-term pipeline and recent stock rally.
Via
Benzinga
3 Magnificent Stocks to Buy That Are Near 52-Week Lows
February 17, 2025
Via
The Motley Fool
Pfizer's Talzenna/Xtandi Combo Improves Survival Outcomes In Metastatic Castration-Resistant Prostate Cancer
February 14, 2025
Pfizer's TALAPRO-2 study shows Talzenna + Xtandi significantly improves survival in mCRPC patients, with up to a 14-month OS gain in HRR-mutated cases.
Via
Benzinga
Robert F. Kennedy, Vaccine Skeptic, Confirmed As Trump's Secretary Of Health: Health Care Stocks To Watch
February 13, 2025
The U.S. Senate voted on Thursday to confirm President Donald Trump's nomination of Robert F. Kennedy Jr. to lead the Department of Health and Human Services.
Via
Benzinga
Topics
Government
Exposures
Political
Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
February 13, 2025
From
Pfizer Inc.
Via
Business Wire
Zoetis (NYSE:ZTS) Posts Q4 Sales In Line With Estimates But Stock Drops
February 13, 2025
Animal health company Zoetis (NYSE:ZTS) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 4.7% year on year to $2.32 billion. On the other hand, the company’s full-year revenue...
Via
StockStory
3 Brand-Name, Ultra-High-Yield Dividend Stocks Patient Investors Can Confidently Buy With $300 Right Now
February 13, 2025
A trio of high-octane income stocks -- sporting an average yield of 6.65% -- can fatten investors' pocketbooks in 2025 (and well beyond).
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
February 12, 2025
Via
Benzinga
U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
February 12, 2025
From
Pfizer Inc.
Via
Business Wire
Earnings To Watch: Zoetis (ZTS) Reports Q4 Results Tomorrow
February 12, 2025
Animal health company Zoetis (NYSE:ZTS) will be reporting results tomorrow before market open. Here’s what to look for.
Via
StockStory
Organon (OGN) Q4 Earnings Report Preview: What To Look For
February 12, 2025
Pharmaceutical company Organon (NYSE:OGN) will be reporting earnings tomorrow before market hours. Here’s what investors should know.
Via
StockStory
Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo
February 11, 2025
Pfizer and Astellas' Padcev-Keytruda combo showed durable survival benefits in urothelial cancer, with a higher response rate and no new safety concerns.
Via
Benzinga
Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
February 10, 2025
From
Pfizer Inc.
Via
Business Wire
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.